February 26, 2025
1 min watch
Save
VIDEO: RVO often overlooked in retinal space
KOLOA, Hawaii — In this expert perspective from Hawaiian Eye 2025, Roger A. Goldberg, MD, MBA, highlights advancements in the treatment of retinal vein occlusion.
Goldberg discussed the FDA approval of Vabysmo (faricimab, Genentech) for the treatment of retinal vein occlusion (RVO) and the possible label expansion of high-dose aflibercept for the treatment of RVO in the coming year.
“Retinal vein occlusion is kind of the forgotten stepchild of retinal vascular diseases,” Goldberg said. “Remarkably, in the 2024 PAT Survey, there was not a single question about retinal vein occlusion.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio interviews
Disclosures:
Goldberg reports being an investigator and consultant for Apellis.
Read more about